October 2026 changed the phase of the Depo-Provera litigation, not the payout. Cases covered by the summer agreement moved into settlement administration with no public payment amounts. Depo-Provera is injectable medroxyprogesterone acetate, a birth-control shot. The lawsuits allege women who received brand or generic versions later developed intracranial meningioma, a tumor in the membranes around the brain, and that Pfizer failed to warn doctors and patients.
Official resources:
- Read the official notice from Lawyersandsettlements — Use this primary source to verify the official announcement.
- Read the official notice from Tortadvisor — Use this primary source to verify the official announcement.
Table of Contents
- Who do these lawsuits cover?
- What did the July settlement resolve?
- What must eligible claimants do by November 30?
- What happens to cases outside the settlement?
- What evidence and label change sit behind the claims?
Who do these lawsuits cover?
According to AboutLawsuits, 6,412 meningioma lawsuits were pending on October 1, 2026. They sit in federal MDL No. 3140 before Judge M. Casey Rodgers in the Northern District of Florida, as detailed in the federal docket update.
Drugwatch describes the core group as women given brand or generic injectable medroxyprogesterone acetate who later developed intracranial meningioma. Their claims focus on failure to warn doctors and patients about the meningioma risk. The cases are personal-injury mass-tort claims, not a class action with automatic membership. Each claimant must show her own injections and diagnosis.
What did the July settlement resolve?
According to Lawyers and Settlements, Pfizer signed a confidential global Master Settlement Agreement on July 21, 2026. It covers about 80% of roughly 6,400 federal cases plus related New York state-court cases, as reported in the settlement agreement report. TortAdvisor reports that October brought administration, not payouts.
No aggregate fund, per-plaintiff amount, or payment tier was publicly disclosed. That structure is common in large mass torts. Covered cases stop active litigation steps and enter claims review, while payment follows later.
What must eligible claimants do by November 30?
TortAdvisor reports that eligible claimants must complete settlement registration by November 30, 2026 under Case Management Order No. 14. BrownGreer PLC serves as administrator, with first payments expected in Q1 2027, as explained in the claims administration update.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Registration is a deadline, not a guarantee of payment. Missing it can exclude an otherwise covered claim from this settlement round. Lawyers and Settlements notes that participation rules and medical-proof standards remained undisclosed in October. Readers with a possible claim can take these practical steps now:.
- preserve shot records, pharmacy records, and clinic notes showing dates and product
- preserve imaging, surgery, and pathology records showing meningioma diagnosis
- seek individual case review before the November deadline
What happens to cases outside the settlement?
Claims outside the settlement continue in court. The Robert King Law Firm update places the Rule 702/Daubert expert-testimony hearing on September 18, 2026, with a first bellwether trial calendared for December 2026. That hearing tests whether plaintiffs' scientific experts may testify at trial.
Bellwether trials test selected cases before a jury and often shape later talks. For readers, the split matters. Settlement participants follow the administrator's process, while nonparticipants face motion practice and trial preparation.
What evidence and label change sit behind the claims?
The European Medicines Agency communication cites a March 2024 French national case-control study in The BMJ. It reported an odds ratio of 5.55 for intracranial meningioma requiring surgery with injectable medroxyprogesterone acetate, driven by prolonged use over one year. Drugwatch reports that the FDA approved a December 2025 Depo-Provera label change adding a meningioma warning.
The warning directs doctors to monitor for symptoms and stop the drug if meningioma is diagnosed. Those two developments do not prove any individual case. They explain why long-term users with surgery-level tumors form the center of the litigation.
You Might Also Like
- VSL#3 Lawsuit Update: What the January 2027 Settlement Hearing Will Decide
- Pharmaceutical Lawsuit Settlement Guide 2026: Eligibility, Evidence, and Deadlines
- Wildfire Lawsuit vs Alternatives: Legal Paths Compared